Market Intelligence, Clinical Progress, and High-Precision Reagents for Cancer Immunotherapy and Inflammatory Disease Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CXCR2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCR2 Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Available in detergent-solubilized or nanodisc formats. |
View CXCR2 Products |
| Gene Delivery | CXCR2 Promise-ORF / Lentivirus Full-length ORF for stable cell lines. Ideal for preserving native 7-transmembrane GPCR conformation. |
View CXCR2 Products |
| Benchmark Ab | Anti-CXCR2 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequences. |
View CXCR2 Products |
| Validator | CXCR2 siRNA Set For gene knockdown and target specificity verification in cell-based assays. |
View CXCR2 Products |
| Related Target A | CXCR1 Highly homologous receptor. Essential for off-target and selectivity counter-screening. |
View CXCR1 Products |
| Related Target B | CXCL8 Primary high-affinity chemokine ligand (IL-8) driving CXCR2 activation and neutrophil chemotaxis. |
View CXCL8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Conformational GPCR Integrity | Lentivirus Premade Particles for stable cell line construction, ensuring native 7-transmembrane folding. |
| Subfamily Off-Target Screening | CXCR1 and CXCR2 sequence-verified expression vectors for parallel specificity assays. |
| Lack of Controls | Clinical-grade Benchmark Antibodies (Biosimilars) available for functional assay validation. |
| False Positives | Sequence-verified siRNA sets included for target knockdown validation. |
Live CXCR2/CD182 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXCR2 therapeutics is intensifying, with major players shifting focus from traditional small molecule monotherapies to combination regimens in oncology. As first-generation CXCR2 antagonists enter advanced clinical stages, the next wave of R&D is targeting the suppression of myeloid-derived suppressor cells (MDSCs) in the tumor microenvironment to overcome resistance to immune checkpoint inhibitors (anti-PD-1/PD-L1).
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule | AstraZeneca, Syntrix, Dompé | COPD, Solid Tumors, Metastatic Melanoma | Selectivity Assay (Need CXCR1 vs CXCR2 stable cell lines for counter-screening) |
| Monoclonal Antibody | Academic Institutions, Biotech Startups | Inflammatory Diseases, Pancreatic Cancer | Epitope Mapping & Binding Affinity (Need native conformation GPCR targets) |
| Combination Therapies | Merck, Bristol Myers Squibb | Advanced Solid Tumors (with anti-PD-1) | Functional Chemotaxis and Calcium Flux Validation (Need high-titer Lentivirus) |